Enjoy complimentary customisation on priority with our Enterprise License!
The global plasma protease C1 inhibitor market size is estimated to grow by USD 2.00 billion, at a CAGR of 7.55% between 2023 and 2028.
The plasma protease C1 inhibitor market is anticipated to grow owing to biopharmaceutical firms' increased attention on developing effective plasma protease C1 inhibitor treatment drugs/therapy for various health conditions like HAE, diabetic macular edema (DME), and others. Several kallikrein inhibitor medicines are now in the preclinical and clinical stages of development. For instance, in March 2022, KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced the initiation of the KVD900 Phase 3 KONFIDENT Clinical Trial evaluating efficacy and safety as the first potential oral, on-demand therapy for HAE attacks. Thus, such an increase in R&D related to plasma protease C1 inhibitors is expected to drive market growth during the forecast period.
Technavio has segmented the market into End-user, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our market research and growth report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies are responsible for procuring, storing, and dispensing this critical medication to patients. One of the key factors driving the growth of the hospital pharmacy segment in the global plasma protease C1 inhibitor market is the rising prevalence of hereditary angioedema worldwide. In addition, hospital pharmacies play a crucial role in ensuring the accessibility and availability of plasma protease C1 inhibitors for HAE patients.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was valued at USD 1.78 billion in 2018. Furthermore, close collaboration between hospital pharmacies and other healthcare providers helps in improving treatment outcomes and patient satisfaction. Thus, by ensuring availability, offering comprehensive pharmaceutical care, and collaborating with healthcare professionals, hospital pharmacies contribute significantly to the successful management of HAE and enhancing patient outcomes, which in turn will drive the growth of the hospital pharmacy segment in the market during the forecast period.
Lyophilization, also known as freeze-drying, is a process that involves removing water from a product while keeping its structure intact. In the context of plasma protease C1 inhibitors, lyophilized forms are utilized to enhance their stability, prolong shelf life, and facilitate ease of storage and transportation. Lyophilized plasma protease C1 inhibitors find extensive application in the treatment of HAE, a rare genetic disorder characterized by recurrent episodes of swelling in various body parts such as the skin, gastrointestinal tract, and respiratory system. Further, the development of lyophilized formulations underscores the commitment of pharmaceutical companies and researchers to address unmet medical needs and improve the lives of patients with rare genetic disorders. Hence, the increased benefits of lyophilized will drive the growth of the lyophilized segment in the market during the forecast period.
The global plasma protease C1 inhibitor market is witnessing substantial growth, and one of the notable segments within it is the injectable segment. Injectable plasma protease C1 inhibitor products are administered directly into the bloodstream to treat various medical conditions, particularly HAE. These injectable therapies are designed to restore or supplement the deficient or malfunctioning C1 inhibitor protein in individuals suffering from this rare genetic disorder. The injectable segment of the global plasma protease C1 inhibitor market focuses on ensuring rapid and effective delivery of C1 inhibitor proteins to address acute HAE attacks. Thus, such innovations aim to enhance convenience, optimize dosage, and improve patient comfort during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Due to increased HAE and increasing R&D investments, North America dominates the plasma protease C1 inhibitor market. The presence of well-established healthcare infrastructure and prominent market participants providing effective treatment options to patients suffering from HAE in North America are important growth drivers.
Additionally, many organizations are spreading awareness about the treatment of HAE, like the US Hereditary Angioedema Association, a non-profit organization dedicated to offering HAE patients access to the latest treatment options and dependable, personal support to address symptoms and the challenges associated with the condition. Hence, such factors are expected to drive market growth in this region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AstraZeneca Plc: The company offers plasma protease C1 inhibitor through its subsidiary Alexion Pharmaceuticals such as Soliris which is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth analysis. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Increasing product approvals/launches of plasma protease C1 inhibitors is the key factor driving market growth. As new treatments and therapies are developed offer better options for patients suffering from hereditary angioedema (HAE) and other related disorders. This has led to increased competition among pharmaceutical companies to bring their products to market, resulting in a surge of approvals and launches. For instance, Takeda Pharmaceutical Co. Ltd. presented seven abstracts regarding its therapeutic options for HAE at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Antonio, Texas, on February 24-27.
Therefore, the market witnessed a surge in product approvals and launches as companies sought to capture a share of the growing demand for C1 inhibitor treatments. This trend of increasing product approvals and launches has ensured a continuous stream of novel therapies entering the market. Additionally, the broader availability of these treatments has led to heightened awareness about HAE and increased diagnosis rates, which will further drive the growth of the market during the forecast period.
Growing adoption of bradykinin B2 receptor antagonists is the primary trend shaping market growth. Plasma protease C1 inhibitors act as a regulatory factor in inhibiting the activation of the complement and contact systems, including the production of bradykinin. However, in certain disorders such as hereditary angioedema (HAE), the levels of plasma protease C1 inhibitors are insufficient, resulting in uncontrolled bradykinin release. To address this issue, Bradykinin B2 receptor antagonists have emerged as a promising therapeutic approach aligned with market trends and analysis.
Additionally, advancements in drug development and increasing research activities in the field of bradykinin-related disorders have expanded the range of available options for the treatment of disorders such as HAE. Pharmaceutical companies are investing in the development of novel Bradykinin B2 receptor antagonists to offer improved efficacy, convenience, and patient compliance. In addition, the rising prevalence of HAE and other related disorders across the world will further fuel the growth of the market during the forecast period.
High cost and complex treatment of plasma protease C1 inhibitor is a challenge that affects market growth. If proper guidelines are not followed during the preparation of therapeutics as well as during consumption, plasma protease C1 inhibitor treatment can become very complicated. Current treatments have some drawbacks, such as infection risk, treatment resistance, low compliance, and side effects. Plasma-based medicines are linked to an increased risk of blood-borne diseases such as human immunodeficiency virus (HIV), hepatitis B, and hepatitis C transmission.
However, even though primary blood screening is performed, the risk of infection transmission during transfusion remains significant. This is due to the occurrence of various pathogen strains, blood purification-resistant pathogens, and the threat of new viruses such as flaviviruses. This leads to the development of negative immunological reactions to blood-based products, resulting in treatment non-compliance. Thus, such factors are expected to impede market growth during the forecast period.
The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends opportunities from 2018 to 2028.
Plasma Protease C1 Inhibitor Market Scope |
|
Report Coverage |
Details |
Page number |
166 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.55% |
Market Growth 2024-2028 |
USD 2.00 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.12 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bio Techne Corp., BioCryst Pharmaceuticals Inc., Biosynth Ltd., Bristol Myers Squibb Co., Cayman Chemical, CSL Ltd., FibroGen Inc., Fresenius SE and Co. KGaA, Gilead Sciences Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Merck KGaA, Novartis AG, Pharming Group NV, Sino Biological Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.